Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Crawford & Company (NYSE: A) named Jemin Thakkar global chief information officer, effective April 1, 2026. Thakkar will report to President & CEO Bruce Swain and lead Crawford’s global IT and technology organization, expanding his prior role as chief information security officer.
The reorganization centralizes IT governance, aims to improve data integration and analytics, clarify accountability for technology investments, accelerate enterprise modernization, and responsibly advance AI with disciplined data and security practices.
Agilent (NYSE: A) on April 1, 2026 announced the BioTek Cytation 9, a new cell imaging multimode reader combining multimode microplate detection with high-content imaging in one platform.
Cytation 9 adds inverted fluorescence and upright imaging optics, a multimode reader module, and claims twice the imaging speed, targeting higher-throughput cell‑based and biochemical workflows for research and drug discovery.
TORM plc (NASDAQ: TRMD A) increased share capital by 43,697 A-shares following exercise of Restricted Share Units on March 31, 2026. 10,634 shares were subscribed at DKK 131.80 and 33,063 at DKK 148.70. Post-issue share capital is USD 1,021,233.39 across 102,123,339 A-shares.
New shares are ordinary, carry dividend and voting rights from issuance, and are expected to list on Nasdaq Copenhagen as soon as possible.
Agilent (NYSE: A) announced FDA approval on March 26, 2026 for PD-L1 IHC 22C3 pharmDx, Code SK006 as a companion diagnostic to identify esophageal or gastroesophageal junction (GEJ) carcinoma patients with PD-L1 CPS ≥ 1 who may be eligible for treatment with KEYTRUDA.
This marks the eighth FDA companion diagnostic indication for 22C3. Agilent reported $6.95 billion revenue for fiscal 2025 and ~18,000 employees.
TORM plc (NASDAQ: TRMD A) increased its share capital by 42,533 A-shares following exercise of Restricted Share Units on March 24, 2026. The new shares were subscribed in cash at DKK 148.70 and correspond to a nominal value of USD 425.33.
After the issue, share capital totals USD 1,020,796.42, divided into 102,079,642 A-shares with a nominal value of USD 0.01 each. The shares carry one vote and are expected to be admitted to trading on Nasdaq Copenhagen.
Crawford & Company (NYSE:A) named W. Bruce Swain Jr. president and chief executive officer, effective immediately on March 23, 2026.
Swain served as interim CEO since January 1, 2026, has more than three decades at Crawford including 19 years as CFO, and will remain on the board. Jesse Crawford Sr. will not stand for reelection at the Annual Shareholder Meeting on May 14, 2026, and will become an honorary board member and emeritus officer after the ASM.
Agilent (NYSE: A) will present advances in precision oncology and digital pathology at USCAP 2026, March 21-26 in San Antonio.
Highlights include a new PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), expanded biomarker testing, and integrated end-to-end digital pathology workflows built around the Dako Omnis family.
TORM plc (A / NASDAQ: TRMD A) disclosed a director transaction dated 12 March 2026. CEO and executive director Jacob Balslev Meldgaard sold 223,555 shares of TORM ordinary shares (ISIN GB00BZ3CNK81) on Nasdaq Copenhagen at DKK 163.46 per share, aggregating to DKK 36,451,115. The notification was filed as an initial notification. Investor relations contact: Mikael Bo Larsen.
Contractor Connection (NYSE:A) announced a strategic partnership with Helixco to integrate Helixco’s time-and-materials validation platform into Contractor Connection’s commercial managed repair program. The partnership aims to add real-time transparency, standardized workflows, auditable documentation and improved billing accuracy across commercial repair projects.
The collaboration pairs Helixco’s validation technology with Contractor Connection’s credentialed contractor network to support consistency, accountability and more predictable commercial repair outcomes for carrier partners and contractors.
TORM plc (NASDAQ: TRMD / TRMD A) increased its share capital by 106,468 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal value of USD 1,064.68. A total of 34,880 shares were subscribed at DKK 131.80 and 71,588 at DKK 148.70.
The new ordinary A-shares carry voting and dividend rights as of issuance, are negotiable instruments, and are expected to be listed on Nasdaq Copenhagen as soon as possible. Transfer restrictions may apply in some jurisdictions, including U.S. securities law. After the increase, share capital totals USD 1,019,306.41 divided into 101,930,641 A-shares.